Innoviva, Inc. (INVA) fair value analysis
Nasdaq · Updated 2026-10-19
INVA price how computed
Forward Fair Value verdict
UndervaluedINVA is trading at a 10–25% discount to estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $20.78
- Sector
- Healthcare
- 12-month range
- $17.57–$24.24
- Market cap
- $1.5B
- From 52-week high
- -14.3%
- Shares outstanding
- 72.2M
- Rank in Healthcare by discount to fair value
- #43 of 108
Last price is our stored weekly price from 2026-10-16, older than the 2026-10-19 run that built this page; the chart runs through 2026-10-16.
Innoviva, Inc. is a biopharmaceutical company that develops and commercializes respiratory medicines, primarily focusing on chronic obstructive pulmonary disease and asthma treatments. The company operates in the United States and internationally, with its primary operations and headquarters based in the United States.
INVA currently ranks #43 of 108 Healthcare stocks by discount to fair value. Its Undervalued verdict is new as of this week's run.
Fundamentals (4 quarters) how computed
- Market cap
- $1.5B
- P/E (trailing)
- 5x
- Revenue (TTM)
- $443M
- Net margin
- 80.6%
- EPS (TTM)
- $4.08
- Gross margin
- 75.8%
- Debt / equity
- 0.22
- Revenue growth (3-yr avg)
- 25.9%
- Shares outstanding
- 72.2M
Derived indicators how computed
- Quality grade
- A
- Margin trend
- Contracting
- 52-week position
- The lower-middle quarter of its range
- DCF cross-check
- Undervalued
Technicals how computed
- RSI (14-day)
- 46 · neutral
- 50-day average
- $20.96
- 200-day average
- $21.82
- Moving-average state
- 50-day below 200-day (death cross state); price below both averages
Dividends how computed
- Dividend
- None in the last 12 months (last ex-date 2015-09-08)
Earnings how computed
- Next earnings report
- 2026-11-04
- Last 8 quarters vs consensus
- 5 beat, 3 missed
- Quarter by quarter
- 2026-06 ▲ beat (+5.4%)
2026-03 ▲ beat (+9.3%)
2025-12 ▲ beat (+238.7%)
2025-09 ▲ beat (+134.8%)
2025-06 ▲ beat (+54.0%)
2025-03 ▼ miss (-325.1%)
2024-12 ▼ miss (-36.6%)
2024-09 ▼ miss (-55.6%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 3 buy · 0 hold · 1 sell (4 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $35
- Target vs last price
- +68.4%
What our data shows for INVA
- Our model validated 14 trailing price-to-earnings windows for INVA, built from quarterly earnings records.
- Shares are trading in the middle of their 12-month price range of $17.57–$24.24.
- The 14-day relative strength index sits at a neutral 46.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for INVA
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent INVA news
TickrTrends' derived news-sentiment signal for INVA is currently leaning positive, computed from recent coverage.
- INVA Assumes Outperform by Oppenheimer -- Price Target Announced at $35 (gurufocus.com, 2026-09-23)
TickrTrends take: Oppenheimer's outperform rating and $35 price target for INVA provides a reference point for assessing whether the stock's current market price aligns with analyst expectations in the Healthcare sector. Given that TickrTrends currently rates INVA as fairly valued, investors should monitor whether the market reprices the stock toward Oppenheimer's target or whether fundamental factors emerge that validate or challenge this valuation perspective. The analyst's positive outlook suggests confidence in INVA's business trajectory, making it relevant to watch how the company's execution tracks against the expectations embedded in both the current valuation and the stated price target.
What people are saying
Follow the INVA conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — INVA's technical trend shifted this week as the 50/200-day moving average relationship moved from a mixed state into a downtrend, indicating weakening price momentum relative to longer-term direction. The valuation verdict improved from fairly valued to undervalued, suggesting the stock may offer better relative value at current levels. These changes reflect increased technical weakness paired with a more attractive pricing posture within the healthcare sector.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — INVA's technical trend shifted this week from a downtrend to a mixed state based on the 50/200-day moving average analysis. The valuation assessment moved from undervalued to fairly valued, reflecting a change in how the stock's price compares to its fundamental metrics. The stock remains in the healthcare sector.
- 2026-10-05 — # INVA Weekly Indicator Summary TickrTrends' derived indicators for INVA shifted this week as the valuation verdict moved from Fairly valued to Undervalued. This change reflects a reassessment of the healthcare company's fundamental metrics relative to current market pricing. The stock now appears to offer more attractive valuation parameters compared to the previous week's assessment.
- 2026-09-28 — INVA has improved its position within the Healthcare sector this week, moving up five spots in the sector discount rank from number 62 to number 57. The stock maintains a fairly valued assessment based on current valuation metrics. This modest improvement suggests INVA has become relatively more attractive compared to its Healthcare peers.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is INVA stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), INVA is trading at a 10–25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.
What is INVA's TickrTrends verdict?
INVA's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.
How does INVA compare to other Healthcare stocks?
INVA ranks #43 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is INVA overbought or oversold?
INVA's 14-day RSI is in neutral territory - neither overbought nor oversold.
Does INVA pay a dividend?
INVA has paid no dividend in the last twelve months; its last ex-dividend date on file was 2015-09-08.
When does INVA report earnings next?
INVA's next earnings report is scheduled for 2026-11-04, per the published earnings calendar.
Does INVA usually beat earnings estimates?
Over its last 8 reported quarters INVA beat the consensus estimate 5 times and missed 3 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about INVA?
Of 4 analysts covering INVA, 3 rate it a buy, 0 a hold and 1 a sell - buy-leaning, with a consensus price target of $35 (+68.4% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
INVA vs BAX · INVA vs BDX · INVA vs DCTH · INVA vs ENSG · INVA vs EXEL